Abstract
Sinonasal inverted papilloma (SNIP) can recur; however, the factors related to tumor recurrence remain unclear. This study aimed to analyze risk factors, including human papillomavirus (HPV) infection, as well as other factors associated with SNIP recurrence. Thirty-two patients who were diagnosed with SNIP and underwent surgery between 2010 and 2019 were enrolled: 24 men and 8 women, with a mean age of 59.2 years. The mean follow-up was 57.3 months. Demographics and information about history of smoking, diabetes mellitus (DM), hypertension, allergic rhinitis, alcohol consumption, tumor stage, surgical approach, and recurrence were reviewed retrospectively. Specimens were investigated using polymerase chain reaction to detect HPV DNA (high-risk subtypes: 16, 18, 31, 33, 35, 52b, and 58; low-risk subtypes: 6 and 11). Seven patients (21.9%) experienced recurrence. HPV DNA was detected in five (15.6%) patients (high-risk subtypes, n = 2; low-risk subtypes, n = 3). Patients with recurrence of SNIP had a higher proportion of young adults and displayed higher rates of HPV infection, DM, and advanced tumor stage than those without recurrence. HPV infection, young adulthood, DM, and advanced tumor stage could be associated with a high recurrence rate, which suggests that patients with these risk factors could require close follow-up after surgery.
Highlights
Sinonasal inverted papilloma (SNIP) is a benign neoplasm of the nasal cavity and paranasal sinuses and accounts for 0.5–4% of primary nasal tumors [1]
Pähler et al reported that patients who presented with recurrent papilloma infection were significantly younger (48.7 years old on average) at the time of initial diagnosis than those (60.2 years old on average) with non-recurrent tumors (p = 0.0194), and multivariate logistic regression revealed that a younger age at initial diagnosis was the strongest risk factor for neoplasm recurrence [19]
This study examined the risk factors for SNIP recurrence after surgical resection
Summary
Sinonasal inverted papilloma (SNIP) is a benign neoplasm of the nasal cavity and paranasal sinuses and accounts for 0.5–4% of primary nasal tumors [1]. SNIP has a tendteonrceycutor (r1e2c–u2r0(%12),–a2n0d%)m, anlidgnmanatlitgrnaannsftotrrmanastfiornmhaatsiobneehnasfobuenedn ifnou3n–7d%ino3f –c7a%seso[f2c]a. STehsus, [m2].aTnhyuesa, rm, nanoysee,aarn, ndotsher,oaantdstuhrrgoeaotnssuragreeoinnstearreesitnetderienstuenddinerusntadnedrsintagndwihnigchwhfaichtofrasc-are troerlsaaterde rteolatutemdotro rteucmurorrernecceu.rrence. TThheeeteitoiloolgoygyofoSfNSINPIrPemreaminasiunns kunnokwnno.wCne.rtCaienrhtayipnohthyepsoetshheasvese bheaevnepbreoepnosperdo,pbousted, cbautsaclaiutysahliatsy nheavsenrebveeernbeestnabeslitsahbeldishfoedr tfhoer tshuespsuecstpeedctfeadctfoarcstoorfssomf osmkionkgi,nagl,learlgleyr,gayn, dand hhuummaannppaappiillloommaavviirruuss((HHPPVV))iinnffeeccttiioonn [[33]]. SSeevveerraall ssttaaggiinngg systems have been indicated to tporporvoivdiedae raerceucrurrernecnecreartaet-ed-rdirvievnenprporgongonsoissis[4[]4.]. FFoorrmmoorreetthhaann 3300 years, HPV hhaass bbeeeennssuussppeecctteeddtotopplalayyaammajaojrororloeleininthtehpeapthatohpoh-yspiholyosgioylogf ySNofIPS.NSIePv.eSreavl esrtualdsiteusdhiaevs eharevpeorretpeodrhteidghheirghHePrVHdPeVtedcettioecntiroantersaitnesriencurercreunrrteSnNt IP ScNasIePsc[a5s–e7s],[b5–u7t]t,hbeuret itshecorentirsacdoicnttorraydicntfoorrymiantfiornmaabtoiount wabhoeutht ewr hHePthVe-rasHsoPcVia-taesdsoScNiaItPedhas SaNhIiPghears raishkigohferrerciusrkreonf crec[u8r,9re].nce [8,9]. TThheererefoforere, ,thtihsistustduydayimaiemdetdo atonaalnyazleyrzieskrifsakctofarcsttohrast tahraetaasrseocaiassteodciwatietdh twheithrecthuer-rerceunrcreenofceSoNfISPN, cIoPn, ctaoinntianigniHngPVHPinVfeicntifoenct,ioans ,waselwl aeslloatshoerthreisrkrifsakctfoarcstosruscshucahs agsea,gsee,xs,ex, mmeeddicicaallhhisistotoryry,,ssmmookkiningg, ,aalclcoohhool lcoconnsusummpptitoionn, t,utummororstsatgaeg,ea,nadndsusrugrigciaclaalpapprporaocahc.h
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
